Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

VTX-2337

Known as: TLR8 Agonist VTX-2337, Toll-like Receptor 8 Agonist VTX-2337 
A small-molecule Toll-like receptor 8 (TLR8) agonist with potential immunostimulating and antineoplastic activities. TLR8 agonist VTX-2337 binds to… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Toll-like receptors (TLRs) are nucleic acid–sensing receptors and have been implicated in mediating pain and itch. Here we report… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Is this relevant?
2016
2016
Purpose: As Toll-like receptors (TLR) are key mediators of immune responses, TLR agonists may be important for augmenting the… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2016
2016
UNLABELLED VTX-2337 (USAN: motolimod) is a selective toll-like receptor 8 (TLR8) agonist, which is in clinical development as an… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
Purpose: Immunotherapy as a treatment for cancer holds the promise of complete and durable tumor remission, yet the… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
Purpose: This phase I, open-label, uncontrolled, ascending-dose study explored the safety, maximum tolerated dose (MTD… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
Review
2014
Review
2014
Overexpression of the epidermal growth factor receptor (EGFR) is a common characteristic of head and neck squamous cell… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2014
2014
TPS3123 Background: The potential for synergy between cytotoxic and immunologic agents is an exciting area of exploration in… Expand
Is this relevant?
2013
2013
BackgroundCetuximab is an anti-epidermal growth factor receptor (EGFR) monoclonal antibody that prolongs survival in the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Purpose: We aim to characterize VTX-2337, a novel Toll-like receptor (TLR) 8 agonist in clinical development, and investigate its… Expand
  • table 1
Is this relevant?
2011
2011
2537 Background: Toll-like receptors (TLRs) have emerged as attractive targets for anti-cancer immunotherapies. VTX-2337 is a… Expand
Is this relevant?